Skip to main content

Highlight Capital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

79
Companies
$1.4B
Total invested
$28.8M
Avg. check
33
Industries
Medical 11Biotechnology 10Health Care 9Biopharma 5Pharmaceutical 5Therapeutics 4+27 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 79
Shenandoah Therapeutics
June 2025

Shenandoah Therapeutics is a biotechnology company.

Health Care · South San Francisco$20.0M Seed
Nuclidium
May 2026

Nuclidium is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics.

Health Care · Basel$33.6M Series B
Allegria Therapeutics
April 2026

Allegria Therapeutics is a biotech firm that engages in the research and treatment of allergy and mast cell-mediated inflammatory diseases.

Biotechnology · Basel$1.5M Grant
ImageneBio
April 2026

ImageneBio is dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases

Biopharma · San Diego$30.0M Post-IPO Equity
Vivatides Therapeutics
April 2026

Vivatides Therapeutics develops RNA treatments to help improve patients' lives using biotechnology research.

Biotechnology · Woburn$54.0M Series A
Nuevocor
May 2025

Nuevocor operates as a preclinical-stage biotech company.

Biopharma · Singapore$45.0M Series B
Rgenta Therapeutics
May 2023

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.

Biotechnology · Cambridge$8.0M Series A
Cullgen
May 2023

Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.

Biotechnology · San Diego$35.0M Series C
SparX Group
December 2021

SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.

Biopharma · Grand Cayman$30.0M Series B
T-CURX
December 2025

T-CURX develops personalized T cell therapies for cancer, leveraging a proprietary platform for improved patient outcomes.

Biotechnology · Würzburg$20.0M Series A
Ultra Social
October 2025

Ultra Social is a AI company that builds generative AI-powered digital human and social media marketing solutions.

Digital Marketing · Sarugakucho$7.6M Series B
Spirit AI
February 2026

Spirit AI builds 'universal brain' for real-world robots.

Artificial Intelligence (AI) · Beijing$290.0M Series A
Yiteng Medical
January 2026

Yiteng Medical is a medical technology company that manufactures imaging components and medical device parts used in diagnostic systems.

Health Diagnostics · Suzhou$14.4M Series A
Spurious
January 2026

Spurious is the developer of the small molecule anti-tumordrug developers.

Health Care · Shanghai$35.0M Seed
Realm of Illumination
January 2026

Realm of Illumination is an AI smarter hardware company that specializes in R&D for AI smart terminal equipment.

Artificial Intelligence (AI)Seed
Shouxing Technology
December 2025

Shouxing Technology is the developer of the Humanoid robot.

Robotics · New CitySeries Unknown
Novachip Microelectronics
November 2025

Novachip Microelectronics is a provider of optoelectronic interconnect chips, focusing on the R&D and sales of such chips.

Energy · Hangzhou$14.1M Angel
USUN BIO
October 2025

USUN BIO is a drug research and development company.

Biotechnology · JiangyinSeries Unknown
AsiaSonic Semiconductor
October 2025

AsiaSonic Semiconductor focuses on three main pan-semiconductor sectors: integrated circuits, displays, and photovoltaics.

Machinery Manufacturing · Hefei$14.0M Series B
Yuansheng Intelligence
September 2025

Yuansheng Intelligence is a manufacturer of intricate rehabilitation and nursing medical hardware.

Manufacturing · DongguangAngel
Sieran Medical
September 2025

Sieran Medical is a medical device company that specializes in minimally invasive surgical treatment solutions for ophthalmology.

Medical · Suzhou$14.0M Series Unknown
E-nitiate Biopharmaceuticals
September 2025

E-nitiate Biopharmaceuticals is committed to the development of innovative drugs for autoimmune diseases, through independent research.

Biopharma · Hangzhou$28.0M Series B
Ennovabio
September 2025

Ennovabio is a Chinese drug developer that focuses on creating drugs targeting brain glioma.

Biopharma · ShanghaiSeries Unknown
XINGYUN GROUP
August 2025

Xingyun Group comprehensive services platform for global commodities.

B2B · ShenzhenSeries Unknown

Where Highlight Capital invests

Medical11
Biotechnology10
Health Care9
Biopharma5
Pharmaceutical5
Therapeutics4

About Highlight Capital's portfolio

How many companies has Highlight Capital invested in?

Highlight Capital has invested in 79 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Highlight Capital invest in?

Highlight Capital's top investment sectors include Medical, Biotechnology, Health Care, Biopharma, Pharmaceutical. The firm invests across 33 different industry categories.

What is Highlight Capital's largest investment?

Among tracked funding rounds, Spirit AI received $290.0M in a Series A round. Highlight Capital's total known invested capital is $1.4B.

What is the average investment size for Highlight Capital?

Highlight Capital's average investment size is $28.8M across its portfolio of 79 companies.

What are Highlight Capital's most recent investments?

Recent Highlight Capital portfolio additions include Shenandoah Therapeutics, Nuclidium, Allegria Therapeutics, ImageneBio, Vivatides Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 79 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →